New injection could ease sleep apnea in people with obesity

This study tests an injectable drug called HRS9531 in people with moderate-to-severe obstructive sleep apnea (OSA) and obesity who already use a breathing machine (PAP) at night. The goal is to see if the drug reduces breathing pauses during sleep and helps with weight loss. About 140 adults aged 18-75 with a BMI of 28 or higher will receive either the drug or a placebo for 52 weeks. Participants must have used PAP for at least 3 months and be willing to pause it briefly for sleep tests.